Advanced searches left 3/3

Urethral Cancer - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 February 2022

* If you want to update the article please login/register

Clinical features and oncological outcomes of primary female urethral cancer.

Purpose Investigation of primary female urethral cancer primary female urethral cancer at a single center investigates the clinical characteristics and treatment results of the disease. Materials and methods We retrospectively reviewed 32 FUC patients from 1997-2017. Systemic chemotherapy was administered to 19 patients, including 14 who underwent radiation therapy. Outcomes included poorest in adenocarcinoma, moderate in apparent cell carcinoma and transitional cell carcinoma, and best in squamous cell carcinoma. Conclusion The development of Fetus urethral lesions should be scrutinized closely to exclude FUC. Although extensive medical intervention, distal urethral SCC was responsive to surgical removal, but proximal urethral AC had poor oncological results even after extensive care.

Source link: https://europepmc.org/article/MED/35050502


Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.

The five-year biochemical disease-free survival increased, without significantly raising toxicity, according to the FLAME trial, which showed that by providing a focal boost to traditional fractionated EBRT in the treatment of localized prostate cancer. In the entire cohort, the aim of the present study was to investigate the connection between radiation exposure to the bladder and urethra, as well as genitourinary toxicity grade 2 in the entire cohort. In addition, studies of associations between the dose to the urethra and bladder, as well as the subdomains urinary frequency, urinary retention, and urinary incontinence were found. Conclusion Following EBRT, further increasing the dose to the bladder and urethra will result in a dramatic rise in GU toxicity. As we have reported that a focal boost is helpful in prostate cancer treatment, a further treatment optimization to raise the focal boost dose without increasing the dose to the urethra and other organs at risk should be a focus for future research.

Source link: https://europepmc.org/article/MED/34968470


Urethra-sparing surgery for a prostate cancer lesion in the anterior urethral zone with magnetic resonance-guided focused ultrasound: a case report.

Prostate cancer is the most common cancer among men worldwide. A common therapeutic intervention for low- to moderately contaminated PCas with a low risk of complications is focused ultrasound. However, bladder outlet obstructions and lesions located in the anterior urethral zone are difficult to treat with this strategy because it is impossible to prevent urethral injury during HIFU therapy, which may exacerbate urethral restriction and bladder outlet obstruction. The patient developed urinary retention after catheter removal less than 48 h after the procedure, which resolved after the second catheter was removed a week later. Compared to baseline results, no significant changes were made in the International Prostate Symptom Score and Quality of Life score, which were found in comparison to baseline scores. The catheter's indwelling time of the catheter should be extended optimally for complete recovery from treatment-related prostate edema around the prostatic urethra to avoid urinary retention.

Source link: https://europepmc.org/article/MED/35116388


Urethra-sparing surgery for a prostate cancer lesion in the anterior urethral zone with magnetic resonance-guided focused ultrasound: a case report

Prostate cancer is the most common cancer among males globally. With a low risk of complications, low-intensity focused ultrasound is the most popular therapeutic option for low- to moderate-risk PCa. However, bladder outlet obstructions are more common in the anterior urethral zone, making it difficult to prevent urethral obstruction during HIFU therapy. The patient developed urinary retention after catheter removal less than 48 hours after the procedure, which resolved after the removal of the second catheter a week later. When compared to baseline results, no significant changes were made in the International Prostate Symptom Score and Quality of Life score. PCa lesions in the anterior urethral zone could be safely used for urethra-guided focused ultrasound surgery without inducing post-treatment urination.

Source link: https://europepmc.org/article/MED/PMC8798845

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions